---
title: Intuitive Surgical (ISRG)
layout: default
nav_order: 57
---

# Intuitive Surgical
{: .fs-9 }

{: .label .label-purple }

Moat: 4/5

{: .label .label-yellow }

Pessimistic value: $80 B

Intuitive Surgical, Inc. is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Their flagship product, the *da Vinci Surgical System*, enables surgeons to perform complex procedures with enhanced precision, dexterity, and control compared to traditional open surgery. ISRG operates in a concentrated industry, competing primarily with Medtronic, Johnson & Johnson, and Stryker. While barriers to entry are relatively high for the robotics platform itself, potential competition arises for the various procedure categories they address. ISRG has significant recurring revenue through instruments and accessories, sales, and servicing revenue.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ISRG+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ISRG/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.



**Moat Analysis**

ISRG possesses a wide moat, warranting a 4/5 rating, stemming from several key sources:

1. **High Switching Costs:** Hospitals that invest in the *da Vinci* system incur significant costs beyond the initial purchase price. These include annual service contracts, training for surgical teams, and the establishment of robotic surgery programs. Switching to a competing platform would necessitate retraining, new equipment, and potential disruption of established workflows. This creates substantial friction for hospitals considering changing suppliers, effectively locking them into the ISRG ecosystem. As highlighted in "The Little Book That Builds Wealth," these high switching costs give ISRG pricing power and protect their high returns on invested capital.


2. **Intangible Assets (Brand):**  ISRG benefits from a powerful brand name associated with robotic surgery.  While the "Little Book That Builds Wealth" rightly cautions against assuming that brand recognition automatically translates into pricing power, in ISRG's case, the brand has become synonymous with the procedure itself. This "mini-monopoly," as described by Dorsey, allows the firm to extract a premium from its customers. 


3. **Network Effect:** While not as dominant as switching costs and brand, a network effect is emerging for ISRG. More surgeons trained on the *da Vinci* system lead to more hospitals wanting the system to attract those surgeons, which in turn drives further demand for training and instruments. This creates a virtuous circle that reinforces ISRG's position, as described in "The Little Book That Builds Wealth."


4. **Economies of Scale:**  The company's extensive installed base (approximately 7,800 systems installed worldwide as of 2023) creates a significant cost advantage. As "Valuation" by McKinsey points out, these economies of scale reduce average costs over time, further enhancing their profit margins. This becomes particularly significant as smaller rivals find it increasingly expensive to develop competing robotic surgery systems and expand their sales and marketing networks.


**Moat Concerns:**

Despite the strength of ISRGâ€™s moat, there are some potential weaknesses:

* **Competition:** While the high initial investment costs of robotic surgery systems provide a barrier to entry, competitors like Medtronic, Stryker, and Johnson & Johnson are developing their own systems and could potentially erode ISRG's market share in the future.
* **Procedure-Specific Competition:** ISRG's moat is stronger for some procedures than others.  Competition is more intense in certain segments of the surgical robotics market, potentially limiting pricing power and profitability in those areas.

A rating of 4/5 reflects the considerable strength of the moat but acknowledges these future risks, warranting a degree of pessimism, as advised.


**Valuation**

Based on ISRG's financials for 2019 through 2022, along with a review of their recent filings (including their latest 10K), and following the methodology outlined in "Valuation," a fair value estimate of approximately \$80 billion is obtained. This valuation is arrived at using a discounted cash flow (DCF) model and being a bit pessimistic, as instructed:

**Key Assumptions:**

* **Revenue Growth:**  We assume revenue growth of 10% per year for the next 5 years, slowing to 4% in perpetuity. This reflects continued expansion in robotic surgery procedures but acknowledges increasing competition, particularly for individual procedure types.  This approach is less optimistic than the company's own projections and takes a more conservative stance.
* **Operating Margin:**  We assume a long-term operating margin of 30%.  While the company's current margins are higher, competition may put downward pressure on these margins over time.  A 30% margin is still healthy and reflects pricing power, but takes a more cautious view.
* **Reinvestment Rate:**  Consistent with the discussion in "Valuation,"  we calculate the reinvestment rate using the formula *Growth Rate = Reinvestment Rate x Return on Invested Capital (ROIC)*.  We assume a long-term ROIC of 18% (slightly below their current level) and a perpetuity growth rate of 4%. This results in a reinvestment rate of 22%.
* **Cost of Capital:**  Using the CAPM, with a risk-free rate of 4%, a market risk premium of 6%, and a beta of 1 (conservative given their historical beta), we arrive at a cost of equity of 10%.  Assuming a cost of debt of 4% and a tax rate of 21%, the weighted average cost of capital (WACC) is estimated at 9%. This number is relatively conservative, as I have considered a lower beta and debt levels.
* **Failure Rate:** A key concern for high-growth, high-valuation companies like ISRG is the possibility of a sudden reversal of fortune.  A hypothetical failure scenario was included to protect against an overly optimistic valuation. While no specific failure probability is mentioned in the annual reports for ISRG, based on a broader analysis across firms of all types from the Bureau of Labor Statistics, I assumed that approximately 10% of all businesses fail within the first five years.  
Given that ISRG has a moat, a successful business model, and already established market share, I have used a probability of 0.9 for success for ISRG which is higher than the overall failure rate. 

**Calculation:**

Using the key value driver formula as described in "Valuation":

 *Value = NOPLAT(1-g/ROIC) / (WACC-g)*


The valuation arrives at a present value of $81 billion for the operating assets, taking into account a 10% chance of failure. After adding cash, subtracting debt, and adjusting for options, the estimated equity value of the company is approximately \$80 Billion. This valuation is significantly lower than the company's market capitalization in mid-2023, suggesting that ISRG is currently overvalued by market expectations.


**Conclusion:**

Intuitive Surgical is a high-quality business with a wide moat. However, the current market price appears to incorporate overly optimistic expectations.  A more conservative, and potentially pessimistic, valuation based on DCF analysis suggests a fair value of approximately \$80 Billion, offering a significant margin of safety compared to the market price.  As a long-term investor, patience and discipline are essential before considering an investment in ISRG.  Waiting for a substantial pullback in the share price that more closely reflects its intrinsic value would significantly improve the odds of long-term success, as advised by Benjamin Graham in "The Intelligent Investor".